Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12311403 | 0.81 | EPHX2 (0.34) | ALDH1A1KMT2ARAB9ACHRM1 | |
| SCHEMBL12311413 | 0.77 | EPHX2 (0.34) | ALDH1A1KMT2ARAB9ACHRM1 | |
| SCHEMBL5074820 | 0.76 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL5874768 | 0.74 | ALDH1A1 (0.32) | ALDH1A1KMT2A | |
| SCHEMBL15153153 | 0.74 | ALDH1A1 (0.32) | ALDH1A1KMT2A | |
| SCHEMBL11887150 | 0.74 | ALDH1A1 (0.32) | ALDH1A1KMT2A | |
| SCHEMBL2328907 | 0.74 | CHRM1 (0.35) | CHRM1 | |
| SCHEMBL8827349 | 0.74 | SLC6A2 (0.35) | — | |
| SCHEMBL6944682 | 0.72 | DPP4 (0.33) | — | |
| SCHEMBL7718861 | 0.72 | ALDH1A1 (0.36) | ALDH1A1TDP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9636412-B2 | Conjugates of an anti-TNF-alpha antibody | NEKTAR THERAPEUTICS (US) | 2017-05-02 | — | — | US | disclosed |
| US-20160030587-A1 | CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY | NEKTAR THERAPEUTICS | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160030587-A1 | CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY | TNF, TNFRSF1A, TNFRSF9 | ALDH1A1 2494/4885TDP1 1186/4885KMT2A 4160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.